Skip to main content
Top
Published in: Clinical Rheumatology 4/2007

01-04-2007 | Case Report

Peritoneal mesothelioma: an unusual cause of an acute phase response presenting to the rheumatologist

Authors: S. S. Hamdulay, H. T. Cook, N Strickland, K. A. Davies, J. C. Mason

Published in: Clinical Rheumatology | Issue 4/2007

Login to get access

Abstract

The presence of an acute phase response may pre-date the eventual diagnosis of malignant disease by months or even years. We describe two patients referred to the rheumatology clinic, in which extensive investigation failed to identify an underlying cause to account for the presenting symptoms and an associated acute phase response. Several months later, repeated abdominal CT scans revealed an abnormality and subsequent laparoscopic biopsy confirmed a diagnosis of peritoneal mesothelioma.
Literature
1.
go back to reference Anderson JH, Stewart CJ, Hansell DT, Anderson JR (1990) Peritoneal mesothelioma. Postgrad Med J 66:866–868PubMedCrossRef Anderson JH, Stewart CJ, Hansell DT, Anderson JR (1990) Peritoneal mesothelioma. Postgrad Med J 66:866–868PubMedCrossRef
2.
go back to reference Brenner J, Sordillo PP, Magill GB, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313PubMed Brenner J, Sordillo PP, Magill GB, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313PubMed
3.
go back to reference Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM (1982) Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 96:746–755PubMed Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM (1982) Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 96:746–755PubMed
4.
go back to reference Dach J, Patel N, Patel S, Petasnick J (1980) Peritoneal mesothelioma: CT, sonography, and gallium-67 scan. AJR Am J Roentgenol 135:614–616PubMed Dach J, Patel N, Patel S, Petasnick J (1980) Peritoneal mesothelioma: CT, sonography, and gallium-67 scan. AJR Am J Roentgenol 135:614–616PubMed
5.
go back to reference Smith TR (1994) Malignant peritoneal mesothelioma: marked variability of CT findings. Abdom Imaging 19:27–29PubMedCrossRef Smith TR (1994) Malignant peritoneal mesothelioma: marked variability of CT findings. Abdom Imaging 19:27–29PubMedCrossRef
6.
go back to reference Clark JR, Ross WB (2000) An unusual case of ascites: pitfalls in diagnosis of malignant peritoneal mesothelioma. Aust N Z J Surg 70:384–388PubMedCrossRef Clark JR, Ross WB (2000) An unusual case of ascites: pitfalls in diagnosis of malignant peritoneal mesothelioma. Aust N Z J Surg 70:384–388PubMedCrossRef
7.
go back to reference Chu CM, Lin SM, Peng SM, Wu CS, Liaw YF (1994) The role of laparoscopy in the evaluation of ascites of unknown origin. Gastrointest Endosc 40:285–289PubMedCrossRef Chu CM, Lin SM, Peng SM, Wu CS, Liaw YF (1994) The role of laparoscopy in the evaluation of ascites of unknown origin. Gastrointest Endosc 40:285–289PubMedCrossRef
8.
go back to reference Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM (2003) Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44:1407–1412PubMed Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM (2003) Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44:1407–1412PubMed
9.
go back to reference Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 24:105–119PubMed Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR (2004) Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 24:105–119PubMed
10.
go back to reference Fitzpatrick DR, Manning LS, Musk AW, Robinson BW, Bielefeldt Ohmann H (1995) Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 21:273–288PubMedCrossRef Fitzpatrick DR, Manning LS, Musk AW, Robinson BW, Bielefeldt Ohmann H (1995) Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 21:273–288PubMedCrossRef
11.
go back to reference Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMed Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMed
12.
go back to reference Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunotheras 50:226–227CrossRef Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunotheras 50:226–227CrossRef
Metadata
Title
Peritoneal mesothelioma: an unusual cause of an acute phase response presenting to the rheumatologist
Authors
S. S. Hamdulay
H. T. Cook
N Strickland
K. A. Davies
J. C. Mason
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0171-4

Other articles of this Issue 4/2007

Clinical Rheumatology 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.